Alexis Moscoso Rial, PhD, University of Gothenburg, Gothenburg, Sweden, discusses some of the limitations of [18F]flortaucipir (FTP) imaging. [18F]FTP is a novel form of tau-PET imaging that has recently been approved by the US Food and Drug Administration (FDA) and allows for the in vivo visualization of aggregated tau. While FTP-PET can accurately differentiate healthy controls from subjects with clinically diagnosed Alzheimer’s disease, the major limitation of this imaging technique is that it can only detect advanced Braak stages (Braak stages V and VI). Despite this, it is still able to identify cognitively unimpaired individuals at risk of developing clinical symptoms. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
